OTCMKTS:EDTXF Spectral Diagnostics (EDTXF) Stock Price, News & Analysis $1.01 +0.00 (+0.47%) As of 08/11/2026 11:34 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesShort InterestBuy This Stock About Spectral Diagnostics Stock (OTCMKTS:EDTXF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Spectral Diagnostics alerts:Sign Up Key Stats Today's Range$1.00▼$1.0150-Day Range$0.92▼$1.0252-Week Range$0.59▼$1.31Volume15,100 shsAverage Volume8,380 shsMarket Capitalization$295.02 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada. Read More Spectral Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks1st Percentile Overall ScoreEDTXF MarketRank™: Spectral Diagnostics scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Spectral Diagnostics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Spectral Diagnostics is -10.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spectral Diagnostics is -10.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the float of Spectral Diagnostics has been sold short.Short Interest Ratio / Days to CoverSpectral Diagnostics has a short interest ratio ("days to cover") of 1.38, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Spectral Diagnostics has recently increased by 369.16%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSpectral Diagnostics does not currently pay a dividend.Dividend GrowthSpectral Diagnostics does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Spectral Diagnostics this week, compared to 0 articles on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Spectral Diagnostics insiders have not sold or bought any company stock.Percentage Held by Insiders1.50% of the stock of Spectral Diagnostics is held by insiders.Percentage Held by InstitutionsSpectral Diagnostics has minimal institutional ownership at this time.Read more about Spectral Diagnostics' insider trading history. Receive EDTXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spectral Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EDTXF Stock News HeadlinesSpectral Medical Announces U.S. FDA Filing of PMA Application for PMXJune 25, 2026 | globenewswire.comSpectral Medical Inc. Announces Results of Annual and Special Meeting of ShareholdersJune 9, 2026 | globenewswire.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. | Profits Run (Ad)Spectral Medical and Vantive Announce Topline 12 Month Follow-Up Results From Spectral's Tigris TrialJune 4, 2026 | globenewswire.comSpectral Medical Announces PMA Submission to U.S. FDA for PMXMay 29, 2026 | globenewswire.comSpectral Medical Announces First Quarter 2026 Financial Results and Provides Corporate UpdateMay 8, 2026 | globenewswire.comSpectral Medical Announces Fourth Quarter and Fiscal 2025 Results and Provides Corporate UpdateMarch 26, 2026 | globenewswire.comSpectral Medical and Vantive Announce Publication of Complete Results from Spectral's Tigris Trial in the Lancet Respiratory MedicineMarch 24, 2026 | globenewswire.comSee More Headlines EDTXF Stock Analysis - Frequently Asked Questions How have EDTXF shares performed this year? Spectral Diagnostics' stock was trading at $1.02 at the beginning of 2026. Since then, EDTXF shares have decreased by 1.5% and is now trading at $1.0050. How were Spectral Diagnostics' earnings last quarter? Spectral Diagnostics Inc. (OTCMKTS:EDTXF) issued its quarterly earnings results on Friday, May, 8th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.00. The company had revenue of $0.64 million for the quarter, compared to the consensus estimate of $0.54 million. How do I buy shares of Spectral Diagnostics? Shares of EDTXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/08/2026Today8/11/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolOTCMKTS:EDTXF Previous SymbolOTCMKTS:DIAGF CIKN/A Webwww.spectraldx.com Phone(416) 626-3233Fax416-626-7383Employees29Year Founded1991Profitability EPS (Trailing Twelve Months)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.13 million Net Margins-1,393.13% Pretax Margin-1,373.33% Return on EquityN/A Return on Assets-572.47% Debt Debt-to-Equity RatioN/A Current Ratio0.06 Quick Ratio0.05 Sales & Book Value Annual Sales$1.75 million Price / Sales168.58 Cash FlowN/A Price / Cash FlowN/A Book Value($0.17) per share Price / Book-5.91Miscellaneous Outstanding Shares293,550,000Free Float289,151,000Market Cap$295.02 million OptionableNot Optionable Beta0.13 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:EDTXF) was last updated on 8/12/2026 by MarketBeat.com Staff. From Our PartnersThis Junior Silver Explorer Is Closing In on Its Biggest CatalystA past-producing Nevada silver project holds a historical 36 million ounce silver-equivalent resource, plus mo...Wall Street Logic | Sponsored7 Bankers Met in Secret (Now We Pay for It)A little-known meeting in 1910 cost the average American family their entire financial freedom. They met in se...Decentralized Masters | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe oil crisis is spreading faster than you thinkTanker traffic through Hormuz has plunged from 110-130 daily transits to near zero, while 17% of Qatar's LNG c...Golden Portfolio | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spectral Diagnostics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spectral Diagnostics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
